.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,294,636

« Back to Dashboard

Claims for Patent: 5,294,636

Title: Crystalline form of indole derivative and pharmaceutical method thereof
Abstract:A physical form of N-[4-[5 -(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxybenzoyl ]-2-methylbenzenesulphonamide substantially free of other physical forms, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks occuring at 2.theta.=8.1, 13.7, 16.4, 20.5 and 23.7.degree. and an infra-red spectrum (0.5% in KBr) having sharp peaks at 3370, 1670, 1525, 1490, 1280, 890, 870 and 550 cm.sup.-1, a process for its preparation and pharmaceutical compositions containing it. Also disclosed is a flowable preparation of the physical form which is in the form of soft pellets, and a process for obtaining this preparation.
Inventor(s): Edwards; Martin P. (Bollington, GB2), Sherwood; John D. (Congleton, GB2)
Assignee: Imperial Chemical Industries plc (London, GB2)
Application Number:07/805,426
Patent Claims: 1. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks occuring at 2.theta.=8.1.degree., 13.7.degree., 16.4.degree., 20.5.degree. and 23.7.degree.; an infra-red spectrum (0.5% in KBr) having sharp peaks at 3370, 1670, 1525, 1490, 1280, 890, 870 and 550 cm.sup.- ; and a melting point in the range of 190.degree. to 200.degree. C.

2. A pharmaceutical composition, which comprises an effective amount of a physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl-indol-3-ylmethyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide as claimed in claim 1 and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition as claimed in claim 2, which composition is suitable for administration by a metered dose inhaler, and comprises a pharmaceutically acceptable propellant.

4. A composition as claimed in claim 3, in which the propellant comprises trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane or 1,1,1,2-tetrafluoroethane.

5. A physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxyb enzoyl]-2-methylbenzenesulphonamide substantially free of other physical forms, which form is crystalline, has an X-ray powder diffraction pattern with specific peaks occuring at 2.theta.=8.1.degree., 13.7.degree., 16.4.degree., 20.5 .degree. and 23.7.degree.; an infra-red spectrum (0.5% in KBr) having sharp peaks at 3370, 1670, 1525, 1490, 1280, 890, 870 and 550 cm.sup.-1 ; and a melting point in the range of 190.degree. to 200.degree. C. and which is in the form of soft pellets consisting of an agglomeration of particles, at least 90% of which have a diameter of less than 10 microns, which pellets have a diameter in the range of from 50 to 900 microns.

6. A method for antagonising one or more of the actions of leukotrienes in a living mammal, which comprises administering to said mammal an effective amount of a physical form of N-[4-[5-cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl]-3-methoxybe nzoyl]-2-methylbenzene sulphonamide as claimed in claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc